5+ hour, 59+ min ago   (253+ words) “The goal of the guideline is to provide the evidence behind standard-of-care treatments for recurrent ovarian cancer that are comprehensive, literature-based, and accessible,” stated expert panel co-chair Jamie Lesnock, MD, of the University of Pittsburgh Medical Center.2 The panel recommends…...

1+ week, 3+ day ago   (214+ words) A retrospective series found a 75% response rate adding lenvatinib after pembrolizumab progression in dMMR endometrial cancer, said Susana Campos, MD, MPH. CancerNetwork: How critical is the duration of the IO-free interval when considering a rechallenge? Is a consensus emerging for…...

2+ week, 5+ day ago   (200+ words) Age of 35 years or older, stage III/IV disease, and nondysgerminoma histology were linked with worse cancer-specific survival in malignant ovarian germ cell tumors. The 10-year estimated CSS for dysgerminoma and grade 2/3 immature teratoma was 94.7% (95% CI, 84.4%-98.3%) and 97.5% (95% CI, 83.4%-99.6%), respectively. Other…...

2+ week, 6+ day ago   (313+ words) The FDA granted fast track designation to BI-1808 plus pembrolizumab, which produced a 24% confirmed ORR in pretreated platinum-resistant ovarian cancer. The combination was overall well tolerated, with low rates of grade 3 or higher adverse effects (AEs) and treatment-related discontinuations occurring…...

5+ mon, 1+ week ago   (145+ words) Yesne Alici, MD, explained that while both "chemobrain" and dementia involve memory lapses like misplacing items, chemobrain is typically related to cancer treatment and is often temporary. These cognitive changes can be more pronounced and persistent during treatment, but they…...

9+ mon, 1+ week ago   (754+ words) Because EVA1 is not expressed in normal cells, there may be less toxicity when targeting it to eliminate glioblastoma-initiating cells. Toru Kondo, PhD, presented a seminar at the 16th Annual World Antibody Drug Conjugate (ADC) Summit in San Diego, CA, titled “Evaluating…...